AUS
NZ
UK
CA
USA
IND
Highlights:
-
Bicycle Therapeutics PLC (BCYC) shares rose 5.7% to close at $26.46, supported by significantly increased trading volume.
-
The company's lead drug, zelenectide pevedotin, is currently undergoing evaluation in the phase II/III Duravelo-2 study for metastatic urothelial cancer.
-
Bicycle Therapeutics collaborates with major pharmaceutical companies such as Bayer, Novartis, and Roche to leverage its proprietary platform for developing innovative drugs across various indications.
Description:
Bicycle Therapeutics PLC Sponsored ADR {NASDAQ:BCYC} experienced a notable rise of 5.7% in its stock price during the last trading session, closing at $26.46. This increase was accompanied by substantial trading volume, indicating heightened interest among market participants. This recent performance stands in contrast to the stock's 8.1% decline over the past four weeks, highlighting a shift in sentiment.
The uptick in share price can be attributed to growing enthusiasm surrounding the company’s pipeline of novel molecules, which are being developed using its proprietary technology. Bicycle Therapeutics is advancing its lead drug, zelenectide pevedotin, which is currently in the registrational phase II/III Duravelo-2 study aimed at treating metastatic urothelial cancer. The potential of this drug has garnered attention, as it could address significant unmet medical needs in this patient population.
In addition to its lead candidate, Bicycle Therapeutics has formed collaborations with prominent pharmaceutical companies, including Bayer, Novartis, and Roche. These partnerships aim to utilize Bicycle’s proprietary platform for the development of novel drugs across a range of indications, further expanding the company’s research capabilities and market potential.
Looking ahead, Bicycle Therapeutics is anticipated to report a quarterly loss of $0.78 per share, representing a year-over-year change of 38.1%. Revenue for the quarter is expected to reach $8.16 million, reflecting a significant increase of 52.5% compared to the same period last year.
The consensus earnings per share (EPS) estimate for the upcoming quarter has remained stable over the last 30 days. Historically, a stock's price often does not continue to increase without a corresponding trend in earnings estimate revisions. As such, monitoring BCYC’s performance in the coming weeks will be important to determine if the recent increase can translate into sustained strength.
Currently, Bicycle Therapeutics carries a Zacks Rank of #3 (Hold). The company is part of the Zacks Medical - Biomedical and Genetics industry, which includes other performers such as Voyager Therapeutics (VYGR), whose stock rose 4.5% to $7.18, reflecting a return of 10.5% over the past month.
